Less frequent Ocrevus infusions are just as effective in controlling MS, but may help limit the risk of side effects, per a ...
Real-world discontinuation rates of ocrelizumab are low, similar to pivotal trials, with rates between 3.2% and 4.1% for RRMS and PPMS. Side effects are the most common reason for discontinuation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback